Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
|Poll|June 28, 2018
Mini Quiz: Panic Disorder
Author(s)Andrew W. Goddard, MD
Some patients with panic disorder have chronic, persistent symptoms. Take the quiz and learn more.
Advertisement
Which statement(s) are true of treatment resistant panic (TRP)?
Advertisement
Related to this article
Don't miss out on these CME articles! Test your knowledge here.
Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
3
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
4
Blood-Based Biomarkers for Alzheimer Disease: Accuracy, Limits, and Confounders
5